Acrónimos

3Mdiet tres ingestas diarias
6Mdiet seis pequeñas ingestas
AAS Ácido Acetil Salicílico
AACE/ACE American Association of Clinical Endocrinologists/American College of Endocrinology
ACC American College of Cardiology 
ACCORD Action to Control Cardiovascular Risk in Diabetes Trial.  
ACCORD-BP Action to Control Cardiovascular Risk in Diabetes- Blood Pressure
ACCORDION Action to Control Cardiovascular Risk in Diabetes  Follow ON
ACE2 Angiotensin-Converting Enzyme 2  o enzima convertidora de la angiotensina 2 
ACG AutoControl de Glucemia
ACLS Aerobics Center Longitudinal Study 
ACR Aptitud CardiorRespiratoria
ActRII receptor II de la activina tipo II 
ACV Accidente CerebroVascular 
ADA American Diabetes Association
ADDITION-Cambridge Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in PrimaryCare 
ADH Alcohol DesHidrogenasa 
ADNI AntiDiabéticos No Insulínicos 
ADOPT Diabetes Outcome Progression Trial
ADVANCE Action in Diabetes and Vascular Disease Study
ADVANCE BP Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation  Blood Pressure 
ADVANCE-ON Action in Diabetes and Vascular Disease Study-Observational Study 
AEI Amputaciones Extremidades Inferiores
AFFIRM-AHF Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron Deficient Patients Admitted for Acute Heart Failure
aGLP-1 Análogos del receptor del péptido-1 similar al glucagón
AGREE II Appraisal of Guidelines Research and Evaluation (second version)
AHA American Heart Association
AHEAD Action for Health in Diabetes (Look AHEAD)
AHEI Alternate Healthy Eating Index 
AHRE episodio auricular de frecuencia alta 
AHRQ Agencia para la Investigación y Calidad de la Atención Médica 
AHS-2 Adventist Health Study-2 
AI Auricula Izquierda.
AL Acidosis Láctica
ALLHAT-LLT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
AMPA Automedida domiciliaria de la Presión Arterial.  
ANGII Angiotensina II
AP Atención Primaria
ApCV aptitud cardiovascular 
ARA2 Antagonistas de los Receptores de la angiotensina II
ARIC Atherosclerosis Risk in Communities 
ARNI inhibidores de la neprilisina 
ARRIVE Aspirin to Reduce Risk of Initial Vascular Events
ASCEND A Study of Cardiovascular Events in Diabetes
ASCOT-LLA Anglo-Scandinavian Cardiac Outcomes Trial
ASPREE Aspirin in Reducing Events in the Elderly 
ATC Antithrombotic Trialists’ Collaboration
ATP  Adenosine TriPhosphato
ATP III Adult Treatment Panel III
AUC Área bajo la Curva
BA Bebidas Azucaradas
BARI-2D Bypass Angioplasty Revascularization Investigation 2 Diabetes
BBs Betabloqueantes
BES Binge Eating Scale
BRACE CORONA Continuing Versus Suspending Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among patients hospitalized with coronavirus disease 2019 (COVID-19) infection
BSRA Bloqueo del Sistema Renina-Angiotensina
CAC Cociente Albumina-Creatinina
CAD Cetoacidosis diabética
CANVAS Canagliflozin Cardiovascular Assessment Study
CANTAYA-SU Canagliflozin _treatment and Trial Analysis-Sulfonylurea
CARDIA Coronary Artery Risk Development in Young Adults
CARE Consultation And Relational Empathy
CARMELINA Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus 
CAROLINA CARdiovascular Outcomestudy of LINAgliptin versus glimepiride in patientswithtype 2 diabetes
CASCADE CArdiovaSCulAr Diabetes & Ethanol
CB Cirugía Bariátrica
CC Circunferencia de Cintura
CCAA Comunidades Autonomas
CCS Canadian Cardiovascular Society
CDA Canadian Diabetes Association.
CDC Centers for Disease Control and Prevention
CDF Dosis Fija de Farmacos
CDK273 Chronic kidney disease 273
CDM Core Diabetes Model
CHANCES Consortium on Healthand Ageing Network of Cohorts in Europe and the United State 
CHANCES Consortium on Healthand Ageing Network of Cohorts in Europe and the United State 
CHARM Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity
CHARM-ALTERNATIVE Candesartan in Heart Failure. Assess of Reduction in Mortality & Morbidity. 
CHARM-PRESERVED Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity
CHS Cardiovascular Health Study
CI Cardiopatia Isquémica
CKD-EPI Chronic Kidney Disease Epidemiology 
CK-MB creatinina cinasa, isoenzima específica del miocardio.
CM Cirugía Metabólica
CMD CardioMiopatía Diabética 
Cor-SARS-2 Coronavirus–Severe Acute Respiratory Syndrome Coronavirus 2 and Diabetes Outcomes
CoV Coronavirus   
COVID19 Coronavirus Disease 2019
CPRD Clinical Practice Research Database 
CREDENCE Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation
CV CardioVascular
CVD-REAL Comparative  Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors
DAPA-CKD Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
DAPA-FH Dapagliflozina y Prevención de Resultados Adversos en la Insuficiencia Cardíaca
DARWIN-T2D DAta for Real World evIdeNce in Type 2 Diabetes
DASH diet Dietary Approaches to Stop Hypertension 
DAWN Diabetes Attitudes, Wishes and Needs 
DAWN2 Diabetes Attitudes, Wishes and Needs 2 (segunda edición)
DCCT Diabetes Control and Complications Trial.  
D2d Vitamin D and Type 2 Diabetes
DE Desviación Estandar
DECLARE-TIMI 58 Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58
DEFINE-HF Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients with HF with Reduced Ejection Fraction
DESIR Epidemiological Study on the Insulin Resistance  Syndrome
DET diferencia estimada del tratamiento 
DG Diabetes Gestacional
DiRECT Diabetes Remission Clinical Trial 
DISCOVER DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings
DM Diabetes Mellitus.  
DM1 Diabetes tipo 1
DM2 Diabetes Mellitus tipo 2
DMP Diferencia Media Monderada 
DPAIB Diferencias en la PA entre los brazos 
DPP Diabetes Prevention Program 
DPPOS Diabetes Prevention Program Outcomes Study 
DREAM Diabetes Reduction Assessment with ramipril and rosiglitazone Medication
DS Desviación Estandar
DSM-5 Diagnostic and Statistical Manual of Mental Disorders 5
DSMES Educación y el Apoyo para el Autocontrol de la Diabetes
DT Diferencias de Tasas
EAG Efecto Adverso Grave
EASD European Association for the Study of Diabetes.
EASEL Evidence for Cardiovascular Outcomes With Sodium Glucose Cotrnasporter 2 Inhibitors in the Real Word 
ECA Ensayo Clinico Aleatorizado
ECC Evento Coronario
ECG Electrocardiograma.
ECNICV Ensayos Clínicos Aleatorizados de No Inferioridad CardioVascular 
ECV Enfermedad CardioVascular
ECVa Enfermedad Cardiovascular Arteriosclerótica
EDIC Epidemiology of Diabetes Interventions and Complications 
EDRFA Encuestas Dietéticas Retrospectivas de Frecuencia Alimentaria
EDWPOP European Diabetes Working Party for Older People 
EGIR Grupo europeo para el estudio de la resistencia a la insulina.  
EH Estancia Hospitalaria
ELIXA Evaluation of  LIXisenatide in Acute Coronary Syndrome 
EMD Edema Macular Diabético
EMA Agencia Europea de Medicamentos
EMDAC Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) 
EMPA-HEART CardioLink-6 Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes  Cardiolink-6
EMPA-KIDNEY The Study of Heart and Kidney Protection With Empagliflozin
EMPA-REG OUTCOME Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose 
EMPA-TROPISM Safety and Efficacy of Empagliflozin versus Placebo on Top of Guideline-directed Medical Therapy in Heart Failure Patients with Reduced Ejection Fraction without Diabetes
EMPEROR-Reduced EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction 
EMPEROR-Preserved EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction  
EMPRISE EMPagliflozin compaRative effectIveness  and SafEty
EN Emociones Negativas
EPIC European Prospective Investigation of Cancer
EPIDIAR Epidemiología de la DIABETES y el Ramadán 
EPO Eritropoyetina
ER Ejercicio de Resistencia
ERA Enfermedad Renal Aguda
ERC Enfermedad Renal Crónica
ERT Enfermedad Renal Terminal
erMedDiet energéticamente restrictiva de MedDiet
ES Endocrine Society
ESC European Society of Cardiology
ESCADIANE Estudio sobre las características de los pacientes ancianos con diabetes en España
ESD Efectos Secundarios aDversos
EvCV Evento CardioVascular
EV Estilos de Vida
EXAMINE Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care 
EXSCEL Exenatide Study of Cardiovascular Event Lowering 
FAERS FDA’s Adverse Event Reporting System 
FAH Falta de AdHerencia
FANV Fibrilación Auricular No Valvular
FDA Food Drug Administration
FDPS Finnish Diabetes Prevention Study 
FE Fracción de Eyección  
FEVI Fracción de Eyección del Ventrículo Izquierdo
FFQ Food Frequency Questionnaire
FGe Tasa de Filtración Glomerular estimada
FGm FGe media
FHS Framingham Heart Study
FIGHT Functional Impact of GLP-1 for Heart Failure Treatment 
FORCE Fatty Acids and Outcomes Research Consortium 
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
FRCV Factor de Riesgo Cardiovascular
FSH Hormona Estimulante del Folículo
GAD65 Ácido Glutámico Decarboxilasa 65
GALACTIC-HF Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure
GB Glucosa Basal 
GBA Glucosa Basal Alterada.
GEDAPS Grupo de Estudio para la Diabetes en Atención Primaria de Salud.
GIN Guidelines International Network 
GLY Gliburide
GoDARTS Observacional Genetics of Diabetes Audit and Research in Tayside Scotland
GRADE Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study
GPRD General Practice Research Database  
GTHS Globulina Transportadora de las Hormonas Sexuales
GTZ Glitazonas (Tiazolidinedionas)
HARMONY Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease
HbA1c Hemoglobina glicada, glucada o Glucohemoglobina.
HC Hidratos de Carbono
HCQ HidroxiCloroQuina
HDL-c colesterol ligado a lipoproteínas de alta densidad 
HFSA Heart Failure Society of American 
HGI Hemorragia GastroIntestinal
HH Hiperglucemia Hiperosmolar
HI Hiperinsulinemia.
HIC Hospitalización por Insuficiencia Cardiaca
HOPE Heart Outcomes Prevention Evaluation 
HOT Hypertension Optimal Treatment  
HR Hazard ratio
HRS Health and Retirement Study 
hs-TnT Troponina T ultrasensible
I/E criterios de inclusión/exclusión
IA Inteligencia Artificial
IA-2 antígeno de los islotes-2 
IADPSG International Association of the Diabetes and Pregnancy Study Groups 
IAGG International Association of Gerontology and Geriatrics 
IAM Infarto Agudo de Miocardio 
IC Insuficiencia Cardiaca
IC 95% Intervalo de Confianza del 95%
ICA512 autoantígeno de células de los islotes 512 
ICCa Indice cintura/cadera
ICE Indice cintura/estatura
ICFEP IC con fracción de eyección preservada
ICFER IC con fracción de eyección reducida
ICFErec IC con fracción de eyección del Ventriculo Izquierdo recuperada 
ICi intervalo de confianza incierto
ICL Inercia Clínica
ICSI Institute for Clinical Systems Improvement
ICT Indice CardioTorácico.
IDF International Diabetes Federation.  
iDPP4 Inhibidores de la dipeptidilpeptidasa 4  
IECA inhibidores de la enzima conversora de la angiotensina.
IEV Intervencion en Estilos de Vida
IG Índice Glucémico
IL Interleucina o InterleuKina
IMC Indice de masa corporal.  
IMCMD IMC mayor antes del debut de la DM2 
IMPROVE-IT Improved Reduction of Outcomes: Vytorin Efficacy International Trial
IMVI índice de masa del VI 
InCC índice de depósito Cálcico Coronario
INRA Inhibidores de la Neprilisina y de los  Receptores de Angiotensina 2 
INS Insulina
INSB Insulina Basal
INS DEGL Insulina Degludec
INSIGHT Intervention as a Goal in Hypertension Treatment 
IPAQ-SF Physical Activity Questionnaire Short Form 
IPC índice de peptido C
IQR Rango Interquartil
IPTW sistema de ponderamiento de la posibilidad tratamiento inverso 
IRC Insuficiencia Renal Crónica
IRIS Insulin Resistance Intervention after Stroke
IRR incidence rate ratio 
iSGLT2 Inhibidores del cotransportador de sodio-glucosa 2 
ISO Organización Internacional de Normalización
IT Inercia Terapéutica
ITG Intolerancia a la glucosa
IWGDF International Working Group on the Diabetic Foot 
JUPITER Justification for the Use of statins in Prevention: an Intervention Trial Evaluating rosuvastatin
K+ Potasio
KCCQ Kansas City Cardiomyopathy Questionnaire
KDIGO Kidney Disease: Improving Global Outcomes 
KPNC Kaiser Permanente Northern California 
LDL-col Lipoproteina de baja densidad-colesterol
LEADER Liraglutide Effect and Action in Diabetes: Evaluation of  cardiovascular Outcome Results 
LH Hormona Luteinizante
LIBERATES Improving Glucose Control in Patients With Diabetes Following Myocardial Infarction: The Role of a Novel Glycaemic Monitoring
LINA Linagliptina
LST Life`s Simple 7
LTC Centros de Atención a largo plazo 
MACE Major Adverse Cardiovascular Events (eventos adversos cardiovasculares mayores)
MALE Major Adverse Limb Events
MAPA Monitorización Ambulatoria de la Presión Arterial.
MBE Metodología Basada en la Evidencia  o Medicina Basada en la Evidencia
MCC Muerte por Cualquier Causa
MCP-1 proteína quimiotáctica de monocitos tipo 1
MCV Muerte de causa CardioVascular
MD Mediana de Diferencia de medias
MDRD Modification of Diet in Renal Disease
MEASURE-HF Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
MedDiet Dieta Mediterránea
MMSE Mini-Mental State Examination
MERS Síndrome Respiratorio de Medio Oriente 
MesH Medical Subject Headings
MET Metformina
MEV Modificación en los Estilos de Vida
MFR Multiples Factores de Riesgo
MGC Masa grasa Corporal
MM Masa Magra
MNA Mini Nutritional Assessment
MODY Maturity-Onset Diabetes of the Young 
MSC Ministerio de Sanidad y Consumo
MTP Medicamento Tradicional a base de Plantas
MUFA Mono- Unsaturated Fatty Acids
MUST Malnutrition Universal Screening Tool
Na Sodio
NA Neuropatía Autonómica
NAC Neuropati Autonómica Cardíaca
NDDG National Diabetes Data Group
NCEP US National Cholesterol Education Programme.  
NDEP National Diabetes Education Program 
NDM Nefropatia Diabética
NDMA N_Nitrosodimetilamina
NESDA Netherlands Study of Depression and Anxiety 
NGC National Guidelines Clearinghouse 
NGSP National Glycohemoglobin Standardization Program.  
NHANES National Health and Nutrition Examination Survey 
NHMRC Australian Government National Health and Medical Research Council
NICE National Institute for Clinical Excellence.  
NIDDK National Institute of Diabetes and Digestive and Kidney Diseases
NIH National Institutes of Health
NIS Nationwide Inpatient Sample 
NMA Network-Meta Analysis 
NNH Número necesario a tratar para producir un evento adverso
NNT Número Necesario a Tratar
NNT10 NNT en 10 años
NT-proBNP fracción N terminal de la prohormona del peptido natriurético cerebral 
NYHA New York Heart Association
OBSERVE-4D A real-world meta-analysis of 4 observational databases
ODYSSEY OUTCOMES Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
OMS Organización Mundial de la Salud
OECD Organisation for Economic Co-operation and Development 
ON Óxido Nítrico
ONCE Organización Nacional de Ciegos de España
OR odds ratio 
PA Presión Arterial
PAD Presión Arterial Diastólica
PARADIGM-HF Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction
PARAGON Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction
PARALLAX A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
PAS Presión Arterial Sistólica
PC Perímetro de Cintura
PCDE Primary Care Diabetes Eurrope
PCR prueba de reacción en cadena de la polimerasa
PCSK9 Proprotein Convertasa Subtilisin Kexin 9
PCV13 Polisacaridos conjugada  valente 13
PDA Polish Diabetes Association
PDC Proporción de Días Cubiertos
PDM Pie Diabético
PGA Perfil Glucémico Ambulatorio 
PERCEDIME Prevalencia de la Enfermedad Renal  Crónica En pacientes con DIabetes MEllitus  tipo 2 en las consultas de atención primaria
PIO Pioglitazona
PIONEER Peptide InnOvatioN for Early DiabEtes TReatment 
PHQ-9 Patient Health Questionnaire-9 
PP Prevencion Primaria
PPSV23 VN de polisacáridos 23 valente (PPSV23)
PRED PREDiabetes  
PREDAPS PREDiabetes en Atención Primaria de Salud (Primary Health Care on the Evolution of Patients with Prediabetes )
PREDIMED PREvención con DIeta MEDiterránea
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PROactive PROspective pioglitAzone Clinical Trial In macroVascular Events  
PPROMs Patient reported outcome measures 
PROSPER Pravastatin in elderly individuals at risk of vascular disease 
PRR tasa proporcionales por año
PS Propensity scores (puntaje por propensión)
PTH Paratohormona
PUFA Poly- Unsaturated Fatty Acids
PRIORITY Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria
QALYs años de vida ajustados por calidad neta 
RAMQ Régie de l’assurance maladie du Québec 
RCV Riesgo CardioVascular
RECORD Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes
ReFLeCT Results From Real-World Clinical Treatment With Tresiba® 
REGARDS Reasons for Geographic and Racial Differences in Stroke 
REGICOR Registre Gironí del Cor
REWIND Researching cardiovascular Events with a Weekly INcretin in Diabetes
RI Resistencia a la insulina.
RIGHT Reporting Items for Practice Guidelines in Healthcare
RISE Restoring Insulin Secretion
RMN Resonancia Magnética Nuclear
RMNC Resonancia Magnética Nuclear Cardíaca 
ROCKET AF Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation 
RNAO Registered Nurses' Association of Ontario
ROSE The Retrospective Study of Cardiovascular Events Related to the Use of Glucose-Lowering Drug Treatment in Primary Care 
ROSG Rosiglitazona 
RT-PCR Reverse Transcriptase Polymerase Chain Reaction
RTDM Retinopatia Diabética
RTDML Retinopatia Diabética Leve
RTDMNP Retinopatia Diabética No Proliferativa
RTDMP Retinopatia Diabética Proliferativa
SAVOR-TIMI Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus–Thrombolysis in Myocardial Infarction 
SCORED Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk 
SEARCH SEARCH for Diabetes in Youth 
SIDIAP Spanish Information System for the Development of Research in Primary Care 
SIGN Scottish Intercollegiate Guidelines Network 
SMBG Sistema de Monitorización de Glucosa Basal
SMC Standars of Medical Care
SMG Sistema de Monitorización Continua de Glucosa
SMS Servicio de Mensajes Simples 
SNP nucleótidos de un solo polimorfismo 
SNS Sistema Nacional de Salud
SOG Prueba de tolerancia oral a la glucosa.  
SOLOIST-WHF Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure
SOPQ Síndrome de Ovario Poliquistico
SOS Swedish Obese Subjects  
SOUL A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
SPRINT Systolic Blood Pressure Intervention Trial
SRAS  Síndrome Respiratorio Agudo Severo 
SRAS-cov-2 Síndrome Respiratorio Agudo Severo por CoronaVirus 2  
SSE Situación SocioEconómica
sST2 péptido factor de tumorogenicidad soluble de tipo 2 
STAMPEDE Surgical Therapy and Medications Potentially Eradicate Diabetes Efficiently
STAREE Statins for Reducing Events in the Elderly 
STENO 2 Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.  
STEP Semaglutide for the Treatment of Obesity
STITCH Simplified Treatment Intervention to Control Hypertension
STROBE Strengthening of Reporting of Observational Studies in Epidemiology
SUGAR-DM-HF StUdies of empaGliflozin and its cArdiovascular, Renal and metabolic effects in patients with Diabetes Mellitus and Heart Failure
SURDIAGENE Suivi Rénal, DIAbète de type 2 et GENEtique
SUSTAIN Semaglutide in Subjects with Type 2 Diabetes 
S/V Sacabutril/Valsartan
T1D-GRS puntaje de riesgo genómico de la DM1
TECOS Trial Evaluating Cardiovascular Outcomes with Sitagliptin 
TER Tiempo en Rango Glucemico
THEMIS Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study
THIN The Health Improvement Network 
TMPRRSS2 Transmembrane Serine Protease 2 o Proteasa Transmembrana Serina 2
TIPS-3 The International Polycap Study 3
TODAY Treatment Options for type 2 Diabetes in Adolescents and Youth
TOHB Terapia con Oxígeno HiperBárico 
TOSCA IT Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial 
TPP Tasa de Participación en la Prevalencia
TRIUMPH Triple Pill vs Usual Care Management for Patients With Mild-to-Moderate Hypertension
UAB University of Alabama at Birmingham 
UCI Unidad de Cuidados Intensivos.
UD Úlcera diabética
UKPDS United Kingdom Prospective Diabetes Study Group.
USPSTF US Preventive Services Task Force 
VA Veterans Affairs
VADT Veterans Affairs Diabetes Trial
VD Ventrículo derecho.
VEGF Vascular Endothelial Growth Factor  o factores de inhibición del crecimiento vasculo-endotelial 
VERIFY Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of type 2 diabetes
VERTIS CV eValuation of ERTugliflozin effIcacy and Safety CardioVascular 
VFC Variabilidad de la Frecuencia Cardiaca
VI Ventrículo izquierdo.
VICTORIA VerICiguaT GlObal Study in Subjects With Heart Failure With Reduced EjectIon FrAction
VIVIDD Vildagliptin in Ventricular Dysfunction Diabetes
VN vacuna antineumocócica 
WESDR Wisconsin Epidemiologic Study of Diabetic Retinopathy 
WHI Women’s Health Initiative
WHS Wound Healing Society
ZnT8 antigeno del trasportador de Zinc 8 
Recursos en internet
Diccionario de Siglas Médicas http://www.sedom.es/diccionario/
RAE https://dle.rae.es/

No hay comentarios: